Loratadine Clinical Trials On General Hives Suggested By NDAC Members
This article was originally published in The Tan Sheet
Executive Summary
An OTC switch of Schering-Plough's non-sedating antihistamine Claritin for general hives would require data from an evidence-based study of acute urticaria, Jesse Joad, MD, UC-Davis Medical Center, asserted at a meeting of FDA's Nonprescription Drugs Advisory Committee April 22
You may also be interested in...
Claritin “Market Transition Period” Will Entail Rx Sales Post-OTC Approval
Schering-Plough plans to continue marketing Rx Claritin during a "transition period" following FDA approval of an OTC version of the allergy remedy
Claritin Label May Not Need Physician Diagnosis Statement – Consultant
Physician diagnosis instructions on OTC Claritin labeling would not be necessary if the second generation, non-sedating antihistamine is approved by FDA for a general hives or urticaria claim, according to William Rosenberg, MD, University of Tennessee
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC